BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Actos (Pioglitazone) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Actos (Pioglitazone)\, from ClinicalTrial
 s.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05013255-291@assetmemo.bio
DTSTAMP:20261121T004106Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Actos (Pioglitazone): Phase 2 readout est. (NCT05013255)
DESCRIPTION:Actos (Pioglitazone)\, phase 2.\nStudy: Pioglitazone Therapy Ta
 rgeting Fatigue in Breast Cancer\nEstimated primary completion: December 2
 026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/pioglitazone#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0501325
 5
URL:https://assetmemo.bio/drug/pioglitazone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07604779-291@assetmemo.bio
DTSTAMP:20261121T004106Z
DTSTART;VALUE=DATE:20261203
DTEND;VALUE=DATE:20261204
SUMMARY:Actos (Pioglitazone): Phase na readout est. (NCT07604779)
DESCRIPTION:Actos (Pioglitazone)\, phase na.\nStudy: Enhancing PCOS Managem
 ent for Better Outcomes of Intracytoplasmic Sperm Injection\nEstimated pri
 mary completion: 3 December 2026. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/pioglitazone#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07604779
URL:https://assetmemo.bio/drug/pioglitazone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03866408-291@assetmemo.bio
DTSTAMP:20261121T004106Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Actos (Pioglitazone): Phase 1 readout est. (NCT03866408)
DESCRIPTION:Actos (Pioglitazone)\, phase 1.\nStudy: Insulin Regulation of L
 ipolysis and Lipolysis Proteins\nEstimated primary completion: 30 December
  2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/pioglitazone#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT03866
 408
URL:https://assetmemo.bio/drug/pioglitazone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05753657-291@assetmemo.bio
DTSTAMP:20261121T004106Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Actos (Pioglitazone): Phase 1 readout est. (NCT05753657)
DESCRIPTION:Actos (Pioglitazone)\, phase 1.\nStudy: A Pilot Study of Monito
 ring Insulin Levels and Treating Hyperinsulinemia and Hyperglycemia With P
 ioglitazone in Patients Treated With Alpelisib for Metastatic Breast Cance
 r.\nEstimated primary completion: 31 December 2026. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/pioglitazone#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT05753657
URL:https://assetmemo.bio/drug/pioglitazone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06989723-291@assetmemo.bio
DTSTAMP:20261121T004106Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Actos (Pioglitazone): Phase 4 readout est. (NCT06989723)
DESCRIPTION:Actos (Pioglitazone)\, phase 4\, Type 2 Diabetes.\nStudy: Piogl
 itazone and Empagliflozin for Fatty Liver Disease in Type 2 Diabetes\nEsti
 mated primary completion: 31 December 2026. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/pioglitazone#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06989723
URL:https://assetmemo.bio/drug/pioglitazone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03109288-291@assetmemo.bio
DTSTAMP:20261121T004106Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Actos (Pioglitazone): Phase 1/2 readout est. (NCT03109288)
DESCRIPTION:Actos (Pioglitazone)\, phase 1/2.\nStudy: Targeting Residual Ac
 tivity By Precision\, Biomarker-Guided Combination Therapies of Multiple S
 clerosis (TRAP-MS)\nEstimated primary completion: 1 January 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/pioglitazone#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT03109288
URL:https://assetmemo.bio/drug/pioglitazone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02969798-291@assetmemo.bio
DTSTAMP:20261121T004106Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Actos (Pioglitazone): Phase na readout est. (NCT02969798)
DESCRIPTION:Actos (Pioglitazone)\, phase na\, Type 2 Diabetes.\nStudy: Pre-
 diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Gluco
 se Tolerance (IGT)\nEstimated primary completion: 28 February 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/pioglitazone#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT02969798
URL:https://assetmemo.bio/drug/pioglitazone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05305287-291@assetmemo.bio
DTSTAMP:20261121T004106Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Actos (Pioglitazone): Phase 4 readout est. (NCT05305287)
DESCRIPTION:Actos (Pioglitazone)\, phase 4\, Type 2 Diabetes.\nStudy: Quant
 ifying Hepatic Mitochondrial Fluxes in Humans\nEstimated primary completio
 n: 31 March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pio
 glitazone#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT05305287
URL:https://assetmemo.bio/drug/pioglitazone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06729996-291@assetmemo.bio
DTSTAMP:20261121T004106Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Actos (Pioglitazone): Phase 2 readout est. (NCT06729996)
DESCRIPTION:Actos (Pioglitazone)\, phase 2.\nStudy: Pioglitazone Versus Emp
 agliflozin for Chronic Pancreatitis/Recurrent Acute Pancreatitis/Acute Pan
 creatitis Associated Diabetes Mellitus\nEstimated primary completion: 31 M
 ay 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/pioglitazone
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT067
 29996
URL:https://assetmemo.bio/drug/pioglitazone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07117630-291@assetmemo.bio
DTSTAMP:20261121T004106Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Actos (Pioglitazone): Phase 2 readout est. (NCT07117630)
DESCRIPTION:Actos (Pioglitazone)\, phase 2.\nStudy: An Open-Label\, Bayesia
 n Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer Aft
 er Progression on Standard Therapy\nEstimated primary completion: June 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/pioglitazone#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07117630
URL:https://assetmemo.bio/drug/pioglitazone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07053319-291@assetmemo.bio
DTSTAMP:20261121T004106Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Actos (Pioglitazone): Phase 1 readout est. (NCT07053319)
DESCRIPTION:Actos (Pioglitazone)\, phase 1\, Type 2 Diabetes.\nStudy: SGLT2
 i\, Pioglitazone\, and Ketone Production in T2D\nEstimated primary complet
 ion: 1 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pio
 glitazone#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07053319
URL:https://assetmemo.bio/drug/pioglitazone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07056699-291@assetmemo.bio
DTSTAMP:20261121T004106Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Actos (Pioglitazone): Phase 3 readout est. (NCT07056699)
DESCRIPTION:Actos (Pioglitazone)\, phase 3.\nStudy: SGLT2i\, Pioglitazone\,
  and Ketone Production in T1D\nEstimated primary completion: 1 June 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/pioglitazone#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07056699
URL:https://assetmemo.bio/drug/pioglitazone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06446531-291@assetmemo.bio
DTSTAMP:20261121T004106Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Actos (Pioglitazone): Phase 1 readout est. (NCT06446531)
DESCRIPTION:Actos (Pioglitazone)\, phase 1.\nStudy: Prevention of Progressi
 on of Prediabetes\, Obesity and CV Risk\nEstimated primary completion: Jul
 y 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/pioglitazone#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0644
 6531
URL:https://assetmemo.bio/drug/pioglitazone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05727761-291@assetmemo.bio
DTSTAMP:20261121T004106Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Actos (Pioglitazone): Phase 2 readout est. (NCT05727761)
DESCRIPTION:Actos (Pioglitazone)\, phase 2.\nStudy: Pioglitazone-Metformin 
 Combination Treatment for High Risk Oral Preneoplasia\nEstimated primary c
 ompletion: 30 July 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/pioglitazone#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT05727761
URL:https://assetmemo.bio/drug/pioglitazone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04501406-291@assetmemo.bio
DTSTAMP:20261121T004106Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Actos (Pioglitazone): Phase 2 readout est. (NCT04501406)
DESCRIPTION:Actos (Pioglitazone)\, phase 2\, Type 2 Diabetes.\nStudy: Low-D
 ose Pioglitazone in Patients With NASH (AIM 2)\nEstimated primary completi
 on: 31 August 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/p
 ioglitazone#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT04501406
URL:https://assetmemo.bio/drug/pioglitazone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07848191-291@assetmemo.bio
DTSTAMP:20261121T004106Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Actos (Pioglitazone): Phase 4 readout est. (NCT07848191)
DESCRIPTION:Actos (Pioglitazone)\, phase 4.\nStudy: Rezdiffra® With Concom
 itant Therapies Commonly Used to Treat Comorbidities in Adults With MASH a
 nd F2-F3 Fibrosis\nEstimated primary completion: November 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/pioglitazone#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07848191
URL:https://assetmemo.bio/drug/pioglitazone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02767063-291@assetmemo.bio
DTSTAMP:20261121T004106Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Actos (Pioglitazone): Phase 1/2 readout est. (NCT02767063)
DESCRIPTION:Actos (Pioglitazone)\, phase 1/2.\nStudy: Therapies in Combinat
 ion or Sequentially With Tyrosine Kinase Inhibitors (TKIs) in Chronic Phas
 e Chronic Myelogenous Leukemia Patients in CCR (ACTIW)\nEstimated primary 
 completion: December 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/pioglitazone#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT02767063
URL:https://assetmemo.bio/drug/pioglitazone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02889003-291@assetmemo.bio
DTSTAMP:20261121T004106Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Actos (Pioglitazone): Phase 2 readout est. (NCT02889003)
DESCRIPTION:Actos (Pioglitazone)\, phase 2.\nStudy: Second STOP After Piogl
 itazone Priming in CML Patients\nEstimated primary completion: December 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/pioglitazone#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT02889003
URL:https://assetmemo.bio/drug/pioglitazone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06657209-291@assetmemo.bio
DTSTAMP:20261121T004106Z
DTSTART;VALUE=DATE:20271215
DTEND;VALUE=DATE:20271216
SUMMARY:Actos (Pioglitazone): Phase 4 readout est. (NCT06657209)
DESCRIPTION:Actos (Pioglitazone)\, phase 4\, Type 2 Diabetes.\nStudy: Norma
 l-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or Tirzepa
 tide\nEstimated primary completion: 15 December 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/pioglitazone#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06657209
URL:https://assetmemo.bio/drug/pioglitazone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06336798-291@assetmemo.bio
DTSTAMP:20261121T004106Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Actos (Pioglitazone): Phase 2 readout est. (NCT06336798)
DESCRIPTION:Actos (Pioglitazone)\, phase 2.\nStudy: Bioenergetic Effect of 
 Pioglitazone in CLD-PH\nEstimated primary completion: February 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/pioglitazone#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06336798
URL:https://assetmemo.bio/drug/pioglitazone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05946564-291@assetmemo.bio
DTSTAMP:20261121T004106Z
DTSTART;VALUE=DATE:20280424
DTEND;VALUE=DATE:20280425
SUMMARY:Actos (Pioglitazone): Phase 3 readout est. (NCT05946564)
DESCRIPTION:Actos (Pioglitazone)\, phase 3.\nStudy: A Trial to Evaluate the
  Efficacy of Pioglitazone to Promote Renal Tolerance in ANCA-associated Va
 sculitis - RENATO Trial\nEstimated primary completion: 24 April 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/pioglitazone#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT05946564
URL:https://assetmemo.bio/drug/pioglitazone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06246799-291@assetmemo.bio
DTSTAMP:20261121T004106Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Actos (Pioglitazone): Phase 3 readout est. (NCT06246799)
DESCRIPTION:Actos (Pioglitazone)\, phase 3\, Type 2 Diabetes.\nStudy: Compa
 rative Effectiveness of Two Initial Combination Therapies in Patients With
  Recent Onset Diabetes\nEstimated primary completion: 30 April 2029. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/pioglitazone#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06246799
URL:https://assetmemo.bio/drug/pioglitazone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05838287-291@assetmemo.bio
DTSTAMP:20261121T004106Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Actos (Pioglitazone): Phase 4 readout est. (NCT05838287)
DESCRIPTION:Actos (Pioglitazone)\, phase 4\, Type 2 Diabetes.\nStudy: Piogl
 itazone on Heart Failure in Type-2 Diabetes Mellitus Participants\nEstimat
 ed primary completion: August 2029. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/pioglitazone#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT05838287
URL:https://assetmemo.bio/drug/pioglitazone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
